hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06336226, orgStudyIdInfo id: BB AVF one stage vs two stage, briefTitle: Brachio Basilic Arterio Venous Fistula One Stage vs Two Stage, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this work was to compare primary failure rates and the primary functional patency of one-stage vs two stage brachiobasilic fistulas to compare the two surgical techniques ., conditionsModule conditions: Arterio-venous Fistula, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Brachio basilic arterio venous fistula one stage versus two stage, outcomesModule primaryOutcomes measure: Comparative study between one stage brachio basilic arterio venous fistula versus two stage, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336213, orgStudyIdInfo id: 20240306, briefTitle: Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Petrovsky National Research Centre of Surgery, class: OTHER, descriptionModule briefSummary: According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis., conditionsModule conditions: Aortic Aneurysm and Dissection, conditions: Cardiac Valve Disease, conditions: Thoracic Aortic Aneurysm, conditions: Thoracic Aortic Dissection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Ampicillin-sulbactam, outcomesModule primaryOutcomes measure: Infectious complications rate, secondaryOutcomes measure: Total amount of complicated patients, secondaryOutcomes measure: Mortality, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Length of ICU stay, secondaryOutcomes measure: Multiorgan failure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Petrovsky Research National Centre of Surgery (Petrovsky NRCS), status: RECRUITING, city: Moscow, zip: 119991, country: Russian Federation, contacts name: Artem Gubko, Ph.D., role: CONTACT, phone: +79684241490, email: gubko@artvig.ru, contacts name: Denis Guskov, Ph.D, role: SUB_INVESTIGATOR, contacts name: Boris Akselrod, Ph.D, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 55.75222, lon: 37.61556, hasResults: False
protocolSection identificationModule nctId: NCT06336200, orgStudyIdInfo id: Karabuk-006, briefTitle: Knee Osteoarthritis and Kinesiophobia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Karabuk University, class: OTHER, descriptionModule briefSummary: Kinesiophobia after total knee arthroplasty is an important parameter affecting recovery. However, the relationship between kinesiophobia and the factors it may cause is not clear. Therefore, this study aimed to examine the relationship between kinesiophobia, pain, fear of falling, mobility and proprioception in the early period after total knee arthroplasty., conditionsModule conditions: Knee Osteoarthritis, conditions: Kinesiophobia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Kinesiophobia, primaryOutcomes measure: Severity of pain, primaryOutcomes measure: Functional mobility, primaryOutcomes measure: Proprioception, primaryOutcomes measure: Fear of falling, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Pursaklar Public Hospital, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Musa Gunes, Msc, role: CONTACT, phone: 0 (370) 418 9081, email: musagunes@karabuk.edu.tr, contacts name: Fidan Yılmaz, Msc, role: PRINCIPAL_INVESTIGATOR, contacts name: Emime Emirmahmutoğlu, Bachelors, role: PRINCIPAL_INVESTIGATOR, contacts name: Buğrahan Şahin, MD, role: SUB_INVESTIGATOR, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06336174, orgStudyIdInfo id: Anhui-SIA-cohort, briefTitle: Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Anhui Medical University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients., conditionsModule conditions: Intracranial Atherosclerosis, conditions: Cognitive Impairment, conditions: Cerebrovascular Event, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin, interventions name: Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin, outcomesModule primaryOutcomes measure: The changes in Memory, primaryOutcomes measure: Occurrence of ischemic cerebrovascular events, secondaryOutcomes measure: MoCA (Montreal Cognitive Assessment), secondaryOutcomes measure: MMSE (Mini Mental State Examination), secondaryOutcomes measure: DST (Digital Span Test; Forward and Backward), secondaryOutcomes measure: The Stroop Color Test, secondaryOutcomes measure: CTT (Color Trail Test), secondaryOutcomes measure: CDT (Clock drawing test), secondaryOutcomes measure: VFT (Verbal Fluency Test), secondaryOutcomes measure: HAMD (Hamilton Depression Scale), secondaryOutcomes measure: HAMA (Hamilton Anxiety Scale), secondaryOutcomes measure: MRI measure- resting state MRI images, secondaryOutcomes measure: MRI measures-structural phase MRI images, secondaryOutcomes measure: MRI measures-3D pCASL images, secondaryOutcomes measure: Ultrasound measures-MCA-PI (middle cerebral artery-pulsatility index), secondaryOutcomes measure: Ultrasound measures-IMT (intima-media thickness), secondaryOutcomes measure: Blood Metabolomics measures-CRP (C-reactive protiein), secondaryOutcomes measure: Blood Metabolomics measures-oxLDL(Oxidized low-density lipoprotein), secondaryOutcomes measure: Blood Metabolomics measures-miRNA/microRNA, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anhui Medical University, status: RECRUITING, city: Hefei, state: Anhui, zip: 230032, country: China, contacts name: Qiang Wei, PhD, role: CONTACT, phone: +8618788836237, email: qiangwei_914@126.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06336161, orgStudyIdInfo id: ESPB versus CEI, briefTitle: Comparison Between Ultrasound-Guided Erector Spinae Plane Block Versus Ultrasound-Guided Caudal Injection, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, descriptionModule briefSummary: Patient-controlled analgesia is typically used to relieve postoperative pain. Patient-controlled analgesia, on the other hand, is prone to opioid-related side effects. Furthermore, standard postoperative analgesia has a limited analgesic impact. If postoperative lumbosacral spine pain is not successfully treated, it can progress to chronic pain, compromising patients' quality of life.The methods of access for epidural injections are characterized as transforaminal, interlaminar, or caudal. Caudal epidural injections (CEI) are often utilized as a diagnostic or therapeutic tool in a range of lumbosacral-originating spinal pain problems, and they are especially useful in patients with complicated lumbar epidural access diseases, such as post laminectomy syndrome. It is regarded as a very simple treatment in the realm of interventional pain management, and it is also recognized to have a reduced risk of inadvertent Dural puncture than other epidural techniques, conditionsModule conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Fentanyl, outcomesModule primaryOutcomes measure: Measurement of Post-operative Pain, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Al-Azhar University hospitals, city: Cairo, country: Egypt, contacts name: Mohamed Khalil, Resident, role: CONTACT, phone: +201001297071, email: khalil.mohamed24mkh@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06336135, orgStudyIdInfo id: 23-001, briefTitle: Reduction in Symptoms After Laser Therapy With Acorn aHFS, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Acorn Biolabs Inc., class: INDUSTRY, descriptionModule briefSummary: This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily., conditionsModule conditions: Skin Aging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: autologous hair follicle derived secretome, outcomesModule primaryOutcomes measure: Reduction in severity and duration of symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Rejuuv Medi Spa, city: Markham, state: Ontario, zip: L3R0M3, country: Canada, geoPoint lat: 43.86682, lon: -79.2663, hasResults: False
protocolSection identificationModule nctId: NCT06336122, orgStudyIdInfo id: 83904_1, secondaryIdInfos id: R01DK135885-01, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DK135885-01, briefTitle: OASIS: Peer Support for T2DM in Appalachia (Peer Participant), acronym: OASIS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University of Kentucky, class: OTHER, collaborators name: Department of Health and Human Services, collaborators name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), descriptionModule briefSummary: The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are:Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management?If effective, which facets of the peer model are most effective? Peer coaches will Undergo peer coach training.Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting.Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups., conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 76, type: ESTIMATED, armsInterventionsModule interventions name: Peer Coach Training - Weekly, interventions name: Peer Coach Training - Biweekly, outcomesModule primaryOutcomes measure: Number of participants with change in A1c, secondaryOutcomes measure: Diabetes Empowerment, secondaryOutcomes measure: Quality of Life Index, secondaryOutcomes measure: Social Support, secondaryOutcomes measure: Depression Scale, secondaryOutcomes measure: Problem Areas in Diabetes, secondaryOutcomes measure: Diabetes Self-Management, secondaryOutcomes measure: Acts of Daily Living, secondaryOutcomes measure: Social Network Scale, eligibilityModule sex: ALL, minimumAge: 55 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Barren River Area Development District, status: RECRUITING, city: Bowling Green, state: Kentucky, zip: 42101, country: United States, contacts name: Michelle Hines, role: CONTACT, phone: 270-306-4036, email: michelle@bradd.org, geoPoint lat: 36.99032, lon: -86.4436, locations facility: UK HealthCare, status: RECRUITING, city: Hazard, state: Kentucky, zip: 41701, country: United States, contacts name: Kay Douthitt, MD, role: CONTACT, email: key.douthitt@uky.edu, geoPoint lat: 37.24954, lon: -83.19323, hasResults: False
protocolSection identificationModule nctId: NCT06336109, orgStudyIdInfo id: N-20220063-3, briefTitle: Fragmented Sleep, Pain, and Biomechanics, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-26, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Aalborg University, class: OTHER, descriptionModule briefSummary: This interventional study aims to test the effects of sleep disruption on pain sensitivity and biomechanics in healthy individuals during experimental knee and shoulder pain. The main question the study aims to answer is:1) Does sleep fragmentation increase experimental knee and shoulder pain and what are the underlying mechanisms?Participants will receive two injections a) Hypertonic saline (painful) in the knee and b) hypertonic saline (painful) in the upper arm., conditionsModule conditions: Pain, conditions: Healthy, conditions: Sleep Disturbance, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Hypertonic saline knee and shoulder injection, outcomesModule primaryOutcomes measure: Knee Pain intensity (NRS 0-10), primaryOutcomes measure: Shoulder Pain intensity (NRS 0-10), secondaryOutcomes measure: Pain sensitivity, secondaryOutcomes measure: The Pittsburgh Sleep Quality Index score, secondaryOutcomes measure: The Pain catastrophizing Scale score, secondaryOutcomes measure: The Hospital Anxiety and Depression Scale score, secondaryOutcomes measure: The Knee injury and Osteoarthritis Outcome Score, secondaryOutcomes measure: Rapid Assessment of Physical Activity score, secondaryOutcomes measure: Pain distribution by number of pixels marked on a body chart, secondaryOutcomes measure: Video-based motion capture, otherOutcomes measure: Quality of sleep (NRS 0-100), otherOutcomes measure: Level of rest (NRS 0-100), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Aalborg University, status: RECRUITING, city: Aalborg, state: Nordjylland, zip: 9000, country: Denmark, contacts name: Kristian K Petersen, Dr. Med, role: CONTACT, phone: (+45) 31697510, email: kkp@hst.aau.dk, contacts name: Emma Hertel, M. Sc., role: CONTACT, phone: (+45) 60887473, email: eh@hst.aau.dk, geoPoint lat: 57.048, lon: 9.9187, hasResults: False
protocolSection identificationModule nctId: NCT06336096, orgStudyIdInfo id: VX23-548-017, briefTitle: A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Vertex Pharmaceuticals Incorporated, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants., conditionsModule conditions: Pain, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Suzetrigine, interventions name: Suzetrigine, outcomesModule primaryOutcomes measure: Part A: Maximum Observed Plasma Concentration (Cmax) of SUZ, primaryOutcomes measure: Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of SUZ, primaryOutcomes measure: Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of SUZ, primaryOutcomes measure: Part B: Cmax of SUZ, primaryOutcomes measure: Part B: AUC0-tlast of SUZ, primaryOutcomes measure: Part B: AUC0-inf of SUZ, secondaryOutcomes measure: Part A: Cmax of SUZ Metabolite, secondaryOutcomes measure: Part A: AUC0-tlast of SUZ Metabolite, secondaryOutcomes measure: Part A: AUC0-inf of SUZ Metabolite, secondaryOutcomes measure: Part A: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), secondaryOutcomes measure: Part B: Cmax of SUZ Metabolite, secondaryOutcomes measure: Part B: AUC0-tlast of SUZ Metabolite, secondaryOutcomes measure: Part B: AUC0-inf of SUZ Metabolite, secondaryOutcomes measure: Part B: Safety and Tolerability as Assessed by Number of Participants with AEs and SAEs, secondaryOutcomes measure: Part C: Cmax of SUZ and its Metabolite, secondaryOutcomes measure: Part C: AUC0-tlast of SUZ and its Metabolite, secondaryOutcomes measure: Part C: AUC0-inf of SUZ and its Metabolite, secondaryOutcomes measure: Part C: Safety and Tolerability as Assessed by Number of Participants with AEs and SAEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Celerion - Tempe, status: RECRUITING, city: Tempe, state: Arizona, zip: 85283, country: United States, geoPoint lat: 33.41477, lon: -111.90931, hasResults: False
protocolSection identificationModule nctId: NCT06336083, orgStudyIdInfo id: RC31/23/0618, briefTitle: Familial Form of Carotid Web: a Doppler Ultrasound Study, acronym: Family-WEB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: University Hospital, Toulouse, class: OTHER, descriptionModule briefSummary: There is no evidence of familial forms of carotid web. The aim of this study is to determine the prevalence of carotid web among relatives of patient with carotid web using carotid doppler ultrasound., conditionsModule conditions: Carotid Web, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Doppler ultrasound, outcomesModule primaryOutcomes measure: Evaluation of the prevalence of carotid web by doppler ultrasound in first-degree relatives of patients with carotid web., secondaryOutcomes measure: Description of the clinical characteristics of relatives with carotid web and their index case., secondaryOutcomes measure: Description of the morphological characteristics of relatives with carotid web and their index case., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Toulouse, Purpan, city: Toulouse, zip: 31059, country: France, contacts name: Louis FONTAINE, MD, role: CONTACT, phone: 05 61 77 93 67, phoneExt: +33, email: fontaine.l@chu-toulouse.fr, geoPoint lat: 43.60426, lon: 1.44367, hasResults: False